German pharmaceutical company Bayer AG has been asked to stop the phase III
trials of the drug Alpharadin. Patients who were receiving placebo will be
offered the new medicine. The safety and
tolerability of Alpharadin were consistent during Phase I and Phase II trial
Alpharadin, or radium-223 chloride is exclusively licensed from Norwegian
partner Algeta ASA. The drug met its primary endpoint by improving overall
survival significantly in patients with castration-resistant prostate cancer
(CRPC) and symptomatic bone metastases.
The median overall survival rate was 14 months for patients treated with Alpharadin,
compared with 11.2 months.